HOME > Projects > Regenerative Medicine Unit

D-1

Regenerative Medicine Unit

9F

0903

Establishment of an allogeneic cell transplantation therapy for cartilage repair using the gMSC

The gMSC is based on the invention of a scaffold-free tissue engineered construct derived from stem cells (TEC). The TEC is supported by an enhanced extracellular matrix synthesis from synovium-derived mesenchymal stem cells (MSCs) by ascorbic acid. Along with the TWO CELLS Co. Ltd., we have developed a serum-free, chemically defined culture medium called STK, which has been optimized to enhance the efficiency of MSCs. The STK medium has great advantages, which include the elimination of batch variation, risk of contaminants (viruses, mycoplasma, prions), and risk of allergies to proteins derived from another living organism. The gMSC was produced by the fusion of the inventions described above, and it will improve the possibility of allogeneic transplantation for cartilage repair.

Responsible Department

Department of Orthopaedic Surgery

Research Partner

TWO CELLS COMPANY, LIMITED

Project Members

Principal Investigator

YOSHIKAWA Hideki

Professor

Department of Orthopaedic Surgery

Profile

Members

NAKAMURA Norimasa

Guest Professor

Global Center for Medical Engineering and Informatics

TSUJI Koichiro

President and CEO

TWO CELLS COMPANY, LIMITED

KATO Yukio

Director

TWO CELLS COMPANY, LIMITED

SHAO Jinchang

Department Manager

TWO CELLS COMPANY, LIMITED

HASEGAWA Shin-ichi

Manager

TWO CELLS COMPANY, LIMITED

MATSUMOTO Masaya

TWO CELLS COMPANY, LIMITED

MAEDA Satoshi

TWO CELLS COMPANY, LIMITED

SAKAUE Morito

TWO CELLS COMPANY, LIMITED

IWAMOTO Kaori

TWO CELLS COMPANY, LIMITED

ARAKAWA Hiromi

TWO CELLS COMPANY, LIMITED

YOSHIYAMA Chiharu

TWO CELLS COMPANY, LIMITED

SHIZUKA Takako

TWO CELLS COMPANY, LIMITED

YORITA Mika

TWO CELLS COMPANY, LIMITED

KITAYAMA Yui

TWO CELLS COMPANY, LIMITED

←back